Aaron Tward
Technik-/Wissenschafts-/F&E-Leiter bei AKOUOS
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 7 Jahre |
| Emmanuel J. Simons | M | 41 | 8 Jahre | |
| Charles Sigal | M | 72 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
| Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
| Harry K. Genant | M | 81 |
The University of California, San Francisco
| - |
| Michael J. McKenna | M | 67 | 8 Jahre | |
| Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
| Jessica Chao | F | - |
The University of California, San Francisco
| 10 Jahre |
| Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
| Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
| Carole Faig | F | 62 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
| Christian Heath | M | - | - | |
| Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
| Jennifer A. Wellman | F | 46 | 6 Jahre | |
| Robert Williams | M | 75 |
The University of California, San Francisco
| 14 Jahre |
| Robin Kate Kelley | M | - |
The University of California, San Francisco
| 15 Jahre |
| Kristine Yaffe | M | 61 |
The University of California, San Francisco
| 17 Jahre |
| Danielle Schlosser | M | - |
The University of California, San Francisco
| 11 Jahre |
| Bruce R. Conklin | M | - |
The University of California, San Francisco
| - |
| Catherine Lynch Gilliss | M | 75 |
The University of California, San Francisco
| 7 Jahre |
| Igor J. Barani | M | - |
The University of California, San Francisco
| - |
| Matthew R. Cooperberg | M | - |
The University of California, San Francisco
| - |
| Jeffrey Bluestone | M | 70 |
The University of California, San Francisco
| - |
| Sheng Lee Yi | M | - |
The University of California, San Francisco
| - |
| Stephen B. Shohet | M | 89 |
The University of California, San Francisco
| 48 Jahre |
| Jeffrey Lotz | M | 66 |
The University of California, San Francisco
| - |
| Terence W. Friedlander | M | - |
The University of California, San Francisco
| 13 Jahre |
| Robert Wachter | M | 66 |
The University of California, San Francisco
| - |
| Ramona Doyle | M | 65 |
The University of California, San Francisco
| 13 Jahre |
| Peter Kushner | M | 86 |
The University of California, San Francisco
| - |
| Rebecca Daro | F | - |
The University of California, San Francisco
| - |
| Jean Phillips | F | - | - | |
| Mindy Goldman | F | - |
The University of California, San Francisco
| 31 Jahre |
| James Bennan | M | - |
The University of California, San Francisco
| - |
| Leah Pimentel | F | - |
The University of California, San Francisco
| - |
| Katherine Pollard | F | - |
The University of California, San Francisco
| - |
| Don Woodson | M | - |
The University of California, San Francisco
| - |
| Louise Chu | F | - |
The University of California, San Francisco
| - |
| Joel Palefsky | M | - |
The University of California, San Francisco
| - |
| Kathleen Reape | M | 58 | 3 Jahre | |
| Rob Aboud | M | 59 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
| Jennifer Meaney | F | - | - | |
| Ventsi Kichikov | M | - | - | |
| Kelley Judith | F | - | - | |
| Ann E. Hickox | F | - | - | |
| Tyler Halloran | M | - | - | |
| Aleksandar Rajkovic | M | 60 |
The University of California, San Francisco
| - |
| Jack Taunton | M | - |
The University of California, San Francisco
| - |
| David A. Larson | M | 83 |
The University of California, San Francisco
| 38 Jahre |
| Randall J. Lee | M | - |
The University of California, San Francisco
| - |
| James Pennington | M | 81 |
The University of California, San Francisco
| 38 Jahre |
| David J. Soffa | M | - |
The University of California, San Francisco
| - |
| Nanci Bakar Fredkin | F | - |
The University of California, San Francisco
| - |
| Cynthia J. Kenyon | M | 69 |
The University of California, San Francisco
| - |
| William Michael Kavanaugh | M | 67 |
The University of California, San Francisco
| - |
| Richard H. Chin | M | 57 |
The University of California, San Francisco
| - |
| Bruce M. McNamara | M | - |
The University of California, San Francisco
| - |
| Harvey J. Anderson | M | 61 |
The University of California, San Francisco
| - |
| Leslie Z. Benet | M | 86 |
The University of California, San Francisco
| 55 Jahre |
| Laurence Corash | M | 80 |
The University of California, San Francisco
| 42 Jahre |
| Tony Chou | M | 63 |
The University of California, San Francisco
| - |
| Alan B. Glassberg | M | 87 |
The University of California, San Francisco
| 54 Jahre |
| Kenneth T. Derr | M | 87 |
The University of California, San Francisco
| - |
| Harold Messmer | M | 78 |
The University of California, San Francisco
| - |
| Steven L. Barriere | M | - |
The University of California, San Francisco
| - |
| Mary E. Foley | M | 72 |
The University of California, San Francisco
| - |
| Marcus A. Conant | M | 88 |
The University of California, San Francisco
| - |
| Steven Bryant Porter | M | 66 |
The University of California, San Francisco
| - |
| Andrew Wolff | M | 69 |
The University of California, San Francisco
| 38 Jahre |
| Pamela Palmer | M | 61 |
The University of California, San Francisco
| 28 Jahre |
| Jeffrey Waldman | M | - |
The University of California, San Francisco
| - |
| Fady Malik | M | 60 |
The University of California, San Francisco
| 24 Jahre |
| Steven A. Everett | M | - |
The University of California, San Francisco
| - |
| Philip E. Wolfson | M | 79 |
The University of California, San Francisco
| 38 Jahre |
| Dean Ornish | M | - |
The University of California, San Francisco
| - |
| Carol L. Moss | F | - |
The University of California, San Francisco
| - |
| Deepak Srivastava | M | 57 |
The University of California, San Francisco
| - |
| Mark Smith | M | 72 |
The University of California, San Francisco
| 30 Jahre |
| Narayana S. Ambati | M | - |
The University of California, San Francisco
| - |
| Daniel R. Hightower | M | - |
The University of California, San Francisco
| - |
| David A. Kessler | M | 72 |
The University of California, San Francisco
| 21 Jahre |
| Carol Brosgart | M | 72 |
The University of California, San Francisco
| - |
| H. Perez | M | 74 |
The University of California, San Francisco
| - |
| Hsiao Lieu | M | 53 |
The University of California, San Francisco
| - |
| Michael Rowbotham | M | - |
The University of California, San Francisco
| - |
| Andrew Woeber | M | 56 |
The University of California, San Francisco
| - |
| Vera Price | M | - |
The University of California, San Francisco
| - |
| Kenneth Hao | M | 55 |
The University of California, San Francisco
| - |
| Catherine Friedman | F | 63 |
The University of California, San Francisco
| - |
| Michael McGrath | M | - |
The University of California, San Francisco
| - |
| Marc K. Hellerstein | M | 72 |
The University of California, San Francisco
| 37 Jahre |
| Lee-Ann Murphy | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Arthur Tzianabos | M | 60 | 4 Jahre | |
| Vicki Sato | M | 75 | 2 Jahre | |
| Chris Smith | M | 61 | 4 Jahre | |
| Heather Elizabeth Preston | M | 58 | 2 Jahre | |
| Kush Parmar | M | 42 | 5 Jahre | |
| Philip Johnson | M | 59 | - | |
| Sona Saira Ramasastry | F | 48 | 2 Jahre | |
| Craig Dudenhoeffer | M | - |
The University of California, San Francisco
| 16 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Aaron Tward
- Persönliches Netzwerk
